MX2009001294A - Granulo y tableta que se desintegra por vía oral que comprende oxicodona. - Google Patents

Granulo y tableta que se desintegra por vía oral que comprende oxicodona.

Info

Publication number
MX2009001294A
MX2009001294A MX2009001294A MX2009001294A MX2009001294A MX 2009001294 A MX2009001294 A MX 2009001294A MX 2009001294 A MX2009001294 A MX 2009001294A MX 2009001294 A MX2009001294 A MX 2009001294A MX 2009001294 A MX2009001294 A MX 2009001294A
Authority
MX
Mexico
Prior art keywords
oxycodone
orally disintegrating
granule
disintegrating tablet
granules
Prior art date
Application number
MX2009001294A
Other languages
English (en)
Spanish (es)
Inventor
Didier Hoarau
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38752477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009001294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of MX2009001294A publication Critical patent/MX2009001294A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009001294A 2006-08-04 2007-07-31 Granulo y tableta que se desintegra por vía oral que comprende oxicodona. MX2009001294A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82144906P 2006-08-04 2006-08-04
PCT/EP2007/057912 WO2008015220A1 (en) 2006-08-04 2007-07-31 Granule and orally disintegrating tablet comprising oxycodone

Publications (1)

Publication Number Publication Date
MX2009001294A true MX2009001294A (es) 2009-05-21

Family

ID=38752477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001294A MX2009001294A (es) 2006-08-04 2007-07-31 Granulo y tableta que se desintegra por vía oral que comprende oxicodona.

Country Status (15)

Country Link
US (1) US8465776B2 (enExample)
EP (1) EP2046285B1 (enExample)
JP (1) JP5421775B2 (enExample)
KR (1) KR101445757B1 (enExample)
CN (1) CN101534792B (enExample)
AU (1) AU2007280470B2 (enExample)
BR (1) BRPI0714514B8 (enExample)
CA (1) CA2659122C (enExample)
EA (1) EA017832B1 (enExample)
ES (1) ES2667944T3 (enExample)
IL (1) IL196741A (enExample)
MX (1) MX2009001294A (enExample)
NZ (1) NZ574544A (enExample)
WO (1) WO2008015220A1 (enExample)
ZA (1) ZA200900640B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
PT2046300E (pt) * 2006-08-04 2010-07-01 Ethypharm Sa Comprimido multicamadas de desintegraã†o oral
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
TR201802379T4 (tr) * 2008-10-24 2018-03-21 Toray Industries 4,5-epoksimorfinan türevi içeren stabil tablet.
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
RU2554740C2 (ru) * 2009-05-01 2015-06-27 Апталис Фарматек, Инк. Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en) * 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2012023030A2 (en) * 2010-08-18 2012-02-23 Purdue Pharma L.P. Vacuum avoiding packaging systems and methods thereof
CN102178657B (zh) * 2011-04-11 2017-05-31 浙江华海药业股份有限公司 一种奥氮平口腔崩解片
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
KR101340733B1 (ko) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 신규한 마이크로그래뉼 제형
EP2801349A1 (en) * 2013-05-06 2014-11-12 Siegfried AG Oral Pharmaceutical Formulation
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
GR1008992B (el) 2015-12-17 2017-03-23 Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης
EP3421032A4 (en) * 2016-02-23 2019-10-23 Nipro Corporation PARTICULARS OF A PHARMACEUTICAL COMPOSITION, ORAL DECOMPOSITION PREPARATION THEREOF AND METHOD FOR PRODUCING PARTICLES OF A PHARMACEUTICAL COMPOSITION
JP6915258B2 (ja) * 2016-10-21 2021-08-04 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
KR102120720B1 (ko) * 2018-07-16 2020-06-10 연성정밀화학(주) 날푸라핀 함유 구강붕해정
CN109512796A (zh) * 2018-12-26 2019-03-26 甘肃普安制药股份有限公司 一种氨酚羟考酮胶囊填充方法
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN113842376B (zh) * 2020-06-28 2024-10-11 齐鲁制药有限公司 一种含有利培酮的药物组合物和口溶膜剂及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
CA2128820A1 (en) 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
EP2036558A3 (en) * 1993-10-07 2010-04-28 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
JP2002505269A (ja) 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
US20060182802A1 (en) * 1998-07-28 2006-08-17 Toshihiro Shimizu Rapidly disintegrable solid preparation
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
US6740341B1 (en) * 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
ES2601855T3 (es) * 1998-11-25 2017-02-16 Cima Labs Inc. Comprimido de liberación rápida con núcleo recubierto que contiene el fármaco y capa circundante de enmascaramiento del sabor
FR2790387B1 (fr) 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
AU2002316738B2 (en) * 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ES2616981T3 (es) * 2002-03-14 2017-06-15 Euro-Celtique S.A. Composiciones de hidrocloruro de naltrexona
FR2850576B1 (fr) 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
WO2006127879A1 (en) * 2005-05-26 2006-11-30 Duramed Pharmaceuticals, Inc. Flexible solid dosage forms and methods of making and using the same
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
PT2046300E (pt) * 2006-08-04 2010-07-01 Ethypharm Sa Comprimido multicamadas de desintegraã†o oral

Also Published As

Publication number Publication date
EP2046285B1 (en) 2018-02-21
NZ574544A (en) 2011-12-22
WO2008015220A8 (en) 2008-04-03
US8465776B2 (en) 2013-06-18
JP2009545560A (ja) 2009-12-24
CN101534792A (zh) 2009-09-16
AU2007280470B2 (en) 2013-03-14
ZA200900640B (en) 2010-06-30
EA200900260A1 (ru) 2009-06-30
EA017832B1 (ru) 2013-03-29
BRPI0714514B1 (pt) 2020-01-07
KR20090034372A (ko) 2009-04-07
CA2659122C (en) 2016-08-23
IL196741A0 (en) 2009-11-18
BRPI0714514B8 (pt) 2021-05-25
EP2046285A1 (en) 2009-04-15
KR101445757B1 (ko) 2014-10-02
BRPI0714514A2 (pt) 2013-07-02
US20090304792A1 (en) 2009-12-10
ES2667944T3 (es) 2018-05-16
WO2008015220A1 (en) 2008-02-07
IL196741A (en) 2015-05-31
CN101534792B (zh) 2013-02-20
AU2007280470A1 (en) 2008-02-07
CA2659122A1 (en) 2008-02-07
JP5421775B2 (ja) 2014-02-19

Similar Documents

Publication Publication Date Title
MX2009001294A (es) Granulo y tableta que se desintegra por vía oral que comprende oxicodona.
GB2456989B (en) Granules, tablets and granulation
IL194355A0 (en) Orally disintegrating tablets
EP2218443A4 (en) COMPRESSED ORALLY DISINTEGRATING
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
PL1928882T3 (pl) (S)-N-Metylonaltrekson, sposoby jego syntezy i jego zastosowania farmaceutyczne
JO3757B1 (ar) التركيبات الصيدلانية التي تشمل على نيلوتينيب أو أملاحه
EP1869541A4 (en) COMPUTER MOUSE DEVICES
IL184526A0 (en) Substituted aminomethylene sulphonamides, production and use thereof as medicaments
EP1951203A4 (en) COMPRESSED QUICKLY DISINTEGRATION ORALLY
EP1923074A4 (en) TABLET WHICH CAN BE ORALLY DISINTEGRATED
GB0424323D0 (en) Tablet
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
EA200700023A1 (ru) Разрыхляющаяся при пероральном приёме фармацевтическая композиция, содержащая рисперидон
ZA200902712B (en) Granules, tablets and granulation
ZA200903193B (en) Novel Morphine derivatives
EP1915988A4 (en) COMPRESSOR COMPRISING MULTIPLE SEGMENTS CONTAINING MEDICAMENTS
DE602006008339D1 (en) Zolpidemtabletten
PT1867324T (pt) Comprimido¿
AP2343A (en) Rapidly disintegrating taste-masked tablet.
HK1134916B (en) Granules, tablets and granulation
佚名 et al. Two Pieces of Cake
GB0612183D0 (en) Levothyroxine tablet
PL379680A1 (pl) Granulat aluminiowy
ZAA200500706S (en) Tablet

Legal Events

Date Code Title Description
FG Grant or registration